Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Drug or technology

Repotrectinib

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · PHASE 2 TRIAL

Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis

ClinicalTrials.gov

This is a recruiting Phase 2 trial with no results posted; it describes a planned study of repotrectinib in a specific population but carries no efficacy or safety data yet.

PreliminaryROS1 Gene Rearrangement Brain Metastases MedSIR

Reported

Planned sample size20

Phase2

Primary outcome measureIntracranial Objective Response Rate (IC-OR…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support